Plain-English translation of NCT06596018 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether adding stereotactic body radiation therapy (a precise, focused type of radiation) to your existing can help if your breast cancer tumor hasn't responded well to initial alone. Some patients don't see their tumors shrink after the standard regimen, and this study is exploring whether combining this specialized radiation treatment with continued might improve outcomes for those patients.
Patients whose tumors don't shrink after standard have much higher risks of cancer returning compared to those who respond well to alone. Researchers want to know if adding this targeted radiation therapy early in treatment—before surgery—can improve results and reduce the chance of recurrence in patients whose cancers are resistant to .
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to one of two groups. One group continues with standard only, while the other group receives three doses of focused radiation therapy targeting the tumor area, then continues with the remaining doses. Your doctors will monitor your tumor with physical exams, ultrasound, and MRI scans after each cycle. The study will follow your progress through treatment and afterward to see how well each approach works.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China